

EBMT SURVEY ON TRANSPLANT ACTIVITY 2018

Table 1: Report the number of **patients** receiving their 1st. allogeneic and/or 1st. autologous transplant in 2018 in rows 1-28. Non 1st. HSCT
Table 2: Report the number of **patients** receiving non HSCT cellular therapies in 2018 by indication and cell type.
 Further help can be found in the [guidelines](http://www.ebmt.org) or at www.ebmt.org - report to the activity survey link.



Table 1: Row 1-29 1st transplants only (adults and/or pediatric)		Related									Unrelated			Autologous			Total			No. allo after auto
		HLA-id sibling			Twin	Haplo (≥ 2 loci mismatch)		Other family member			BM	PBSC	Cord	BM	PBSC	Cord	Allo	Auto	Total	
		BM	PBSC	Cord	All	BM	PBSC	BM	PBSC	Cord										
1	AML 1st CR																			
2	AML non 1st CR																			
3	AML therapy related																			
4	AML with myelodysplasia related changes																			
5	ALL 1st CR																			
6	ALL non 1st CR																			
7	CML 1st cP																			
8	CML not 1st cP																			
9	MDS or MDS/MPN																			
10	MPN																			
11	CLL incl. PLL																			
12	PCD - Myeloma																			
13	PCD - other																			
14	HD																			
15	NHL																			
16	Neuroblastoma																			
17	Soft tissue/Ewing sarcoma																			
18	Germ cell tumor																			
19	Breast Cancer																			
20	Other solid tumor																			
21	BM aplasia - SAA																			
22	BM aplasia - other																			
23	Thalassemia																			
24	Sickle cell disease																			
25	Primary immune deficiency																			
26	Inherited disorders of metabolism																			
27	Auto immune disease																			
28	Others (incl. Histiocytosis)																			
29	Total 1st. HSCT (row 1-28)																			
30	No. Additional HSCT																			
31	Total ALL HSCT (= row 29 + 30)																			
32	No. Patients aged <18 reported in row 1-28																			

33 Number of patients receiving DLI infusions in 2018 For graft enhancement/failure: For residual disease: For relapse: Per protocol:

34 Number of Non-Myeloablative (incl. RIC) allogeneic transplants in 2018:

Table 2: No. Patients receiving non HSCT Cellular Therapies using manipulated or selected cells (excluding DLI)

Indication for treatment (Number of patients)	CAR T cells		selected/expanded T cells or CIK		Regulatory T cells (TREGS)		Other genetically modified T cells		NK cells		Dendritic cells		MSC		Expanded CD34+ cells		Genetically modified CD34+		Other therapies (incl. boosts)		
	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	
35	GvHD																				
36	Graft enhancement/failure																				
37	Autoimmune disease																				
38	Genetic disease																				
39	Infection																				
40	Malignancy																				
41	Regenerative medicine																				

Signature.....